GISC protocol experience in the treatment of essential mixed cryoglobulinaemia.

OBJECTIVE: We compared the efficacy of interferon and deflazacort in the treatment of the cryoglobulinaemic syndrome and assessed the usefulness of adding a low antigen diet to drug therapy. METHODS: We studied 63 patients randomly allocated to different groups who underwent clinical and laboratory examinations every two months and who received treatment for 12 months or until a significant clinical event appeared. RESULTS: Five of 28 patients treated with interferon showed clinical improvement whereas 4 worsened and 7 suffered untoward side effects; seven of 28 patients treated with deflazacort improved, 4 worsened and 4 suffered drug toxicity. Twenty-nine patients were assigned to combined low antigen diet and therapy, among whom 7 did not follow the diet, 5 improved and 2 worsened. Among the 34 patients who were on an unrestrained diet, 5 improved and 7 worsened. None of the treatments proved superior to the others. CONCLUSION: Our results do not confirm the suggestion that interferon should be the primary therapy in the treatment of the cryoglobulinaemic syndrome, and the usefulness of a low antigen diet seems minimal.

Sonography after renal biopsy: assessment of its role in 230 consecutive cases.

Among 230 patients undergoing ultrasound (US) guided renal biopsy, 218 had postbiopsy sonography. Clinical records were reviewed to correlate symptoms to US findings. In each case of large hematoma (thickness above 1 cm), all postbiopsy sonographic studies were analyzed to look for findings indicative of unfavorable outcome. A total of 96 subcapsular/perirenal hematomas were found. Large hematomas were observed in 20 patients (20/230 = 8.7%), seven of these (3%) were severely symptomatic. In the absence of clinical signs of bleeding, no patient had clinical consequences. In the presence of clinical signs of bleeding, serious complications occurred only in patients with large hematomas. US thickness of retroperitoneal hematoma correlated to clinical outcome: whenever measured thickness was less than 2 cm, clinical evolution was very favorable, whereas a thickness above 2 cm was invariably associated to clinical signs of bleeding. In six of seven cases of thickness exceeding 3 cm, severe complications developed. An unfavorable evolution was associated with increasing thickness and an echogenicity inappropriate with respect to the time elapsed since biopsy. Hydroureteronephrosis, peritoneal effusion, and anomalous vascular images were indicators of deterioration. We conclude that sonography is indicated only for symptomatic patients and that the monitoring of both thickness and changing echogenicity of retroperitoneal blood collections supplements clinical follow-up.

The clinical significance of IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger's disease).

IgA rheumatoid factor, IgA and IgG immune complexes were measured in 119 patients with IgA nephropathy. IgA rheumatoid factor was detected in 62/119 (52%) patients and in 92/265 (35%) serum samples. There was a good correlation (p less than 0.001) between the presence of IgA rheumatoid factor and the presence as well as levels of IgG immune complexes, but not between levels of IgA rheumatoid factor and other clinical or immunological parameters. However, higher levels of serum IgA were found in the subgroup of patients with constantly positive IgA rheumatoid factor. Using aggregated human IgG, we could not demonstrate antiglobulin activity in renal biopsy specimens from 36 patients. These results suggest that IgA rheumatoid factor does not play a primary role in renal damage in IgA nephropathy, but could simply reflect a response to IgG immune complexes in a disorder characterized by abnormalities of IgA production. Nevertheless, the presence of circulating IgA rheumatoid factor in a substantial proportion of patients, especially in those with features of polyclonal IgA activation, provides additional evidence for a general perturbation of IgA metabolism in this disease and could represent an antigen-specific system with which to study regulation of IgA synthesis.

Food antigens, IgA-immune complexes and IgA mesangial nephropathy.

To investigate whether patients with IgA nephropathy have an exaggerated serum IgA response to ubiquitous food antigens we measured serum IgA antibodies to gliadin, ovalbumin, bovine serum albumin (BSA), beta-lactoglobulin and casein in 120 patients and 53 normal controls, using ELISA. No significant differences were observed between patients and controls in serum IgA antibodies against each of the antigens tested. Moreover, no correlation was found between serum IgA antibodies and IgA-immune complexes (IgA CIC). However, nine patients but no controls had an association of two or more IgA antibodies to dietary antigens. Sixty-six per cent of these patients (vs 24% in the remaining population) had IgA CIC, suggesting a possible involvement of these antibodies in the constitution of IgA CIC. Analysis of sera by HPLC revealed that both monomeric and higher molecular forms of IgA antibodies were present, the latter being coincident with the peak of IgA CIC. Preincubation of sera with serial concentrations of the specific antigen decreased significantly IgA CIC, suggesting that in this subgroup of patients IgA antibodies to food antigens (mainly BSA) are involved in the formation of IgA CIC. BSA-containing IgA CIC were in fact demonstrated by ELISA using rabbit IgG anti-BSA coated plates and peroxidase-conjugated anti-human IgA. The role of these CIC in the pathogenesis of IgA nephropathy needs to be further elucidated.

IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger's disease).

Circulating IgA-antigliadin antibodies were detected with enzyme linked immunosorbent assay (ELISA) in four of 121 patients (3%) who had IgA mesangial nephropathy and 14 of 17 children (82%) who had untreated coeliac disease. No positive cases were present in the 54 healthy subjects of the control group. Three patients who had IgA nephropathy and IgA-antigliadin antibodies underwent jejunal biopsy, and two showed mucosal atrophy. In these two patients urinary abnormalities, together with the IgA-antigliadin antibodies, disappeared completely after three months and five months, respectively, of following a gluten free diet. Circulating IgA immune complexes were found in most patients who had coeliac disease and Berger's disease associated with IgA-antigliadin antibodies, suggesting overactivity of the B cells producing IgA in both conditions. By contrast, a circulating IgA rheumatoid factor was detectable in three of the four patients who had IgA nephropathy and asymptomatic coeliac disease but was always absent in children who had coeliac disease but did not show signs of renal disease. These results suggest that a more complex abnormality in the IgA immune response is necessary for renal disease to become manifest in patients who have gluten enteropathy.

Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up.

Plasma exchange is increasingly used for management of Essential Mixed Cryoglobulinemia. However little is known about the long term effects of this treatment. Therefore we have reviewed the clinical and laboratory data of 20 patients with type II EMC who were followed for a mean of 24 months. 16 patients had renal involvement, which was characterized histologically in all of them: 9 had diffuse proliferative GN plus endoluminal "thrombi" in 6 and vasculitis in 5, 4 had lobular membranoproliferative GN and 3 had focal proliferative GN. 14 patients had renal failure and 13 had proteinuria greater than or equal to 2 g/24 hr. PE (combined with immunosuppressive drugs in 18) was performed for a mean of 18 procedures. The combined treatment induced prompt remission of extrarenal and renal involvement. Serum creatinine and proteinuria decreased significantly in all but 2 patients during the treatment (s. creatinine from 2.9 to 1.6 mg/dl; proteinuria from 3.5 to 1.6 g/24 hr). Analysis of long term follow up revealed that these effects were long lasting in all the cases. We conclude that PE should be used for EMC nephropathy whenever prompt remission is not obtained by conventional therapy especially in consideration of its long term beneficial effects.